[^1]
[^2]
| YWHAE Protein |
|---|
| Protein Name | 14-3-3 Epsilon |
| Gene | YWHAE |
| UniProt ID | P62258 |
| PDB ID | 1a4p, 1g9n, 2b05 |
| Molecular Weight | ~29 kDa (255 aa) |
| Subcellular Localization | Cytoplasm, Nucleus, Mitochondria |
| Protein Family | 14-3-3 family (signaling adaptor/scaffold) |
| Expression | High in brain ([hippocampus](/brain-regions/hippocampus), cortex), ubiquitous |
The YWHAE gene encodes 14-3-3 epsilon, a member of the 14-3-3 protein family that functions as a critical scaffold and adaptor protein in cellular signaling pathways. The 14-3-3 proteins are highly conserved across eukaryotes and regulate diverse cellular processes including signal transduction, cell cycle progression, apoptosis, metabolism, and stress responses 1. In the nervous system, 14-3-3 epsilon plays particularly important roles in neuronal survival, synaptic plasticity, and protection against neurodegeneration 2.
14-3-3 epsilon adopts a distinctive amphipathic groove structure that enables phospho-dependent binding to client proteins:
- Nine α-helices (α1-α9) forming a horseshoe-shaped dimer
- Phosphopeptide-binding groove on each monomer that recognizes phosphorylated serine/threonine motifs (RSXpSXP or pTXY motifs)
- Dimerization interface at the C-terminus creates a functional dimer with two binding pockets
- Each monomer is ~29 kDa; the functional dimer is ~56 kDa
The dimeric structure allows 14-3-3 proteins to simultaneously bind two client proteins, functioning as molecular scaffolds that bring together components of signaling pathways 3.
Seven 14-3-3 isoforms exist in mammals: beta (β), epsilon (ε), eta (η), gamma (γ), theta (θ), zeta/delta (ζ/δ), and sigma (σ). YWHAE is one of the most abundantly expressed isoforms in the brain 4.
14-3-3 epsilon regulates numerous signaling pathways through phospho-dependent client binding:
RAF-MEK-ERK Pathway:
- Binds to and regulates RAF kinases (ARAF, BRAF, CRAF)
- Modulates ERK activation downstream of Ras
- Influences neuronal differentiation and survival
PI3K-AKT Pathway:
- Interacts with AKT/PKB
- Modulates cell survival signaling
- Important for neuronal viability
Cell Cycle Control:
- Binds to CDK-cyclin complexes
- Regulates G1/S and G2/M checkpoints
- Controls entry into mitosis
14-3-3 epsilon is a critical regulator of apoptosis through multiple mechanisms:
BAD Phosphorylation:
- Sequesters BAD in the cytoplasm
- Prevents BAD from inhibiting anti-apoptotic BCL-2 proteins
- Promotes cell survival
ASK1-JNK Pathway:
- Modulates stress-activated kinase pathways
- Regulates JNK and p38 activation
- Controls stress-induced apoptosis
Synaptic Plasticity:
Axonal Transport:
- Binds to microtubule-associated proteins
- Regulates motor protein function
- Ensures proper organelle trafficking
Neuroprotection:
- Protects against oxidative stress
- Modulates autophagy
- Regulates protein quality control
14-3-3 epsilon is extensively implicated in Alzheimer's disease pathogenesis:
Tau Pathology:
- Binds to phosphorylated tau (p-tau)
- May regulate tau phosphorylation by kinases (GSK3β, CDK5)
- Associates with neurofibrillary tangles (NFTs)
- Elevated 14-3-3 epsilon found in AD brain tissue 5
Amyloid-β Interactions:
- Modulates amyloid-β toxicity
- May affect APP processing
- Protects against Aβ-induced apoptosis
Synaptic Dysfunction:
- Altered in AD synaptic compartments
- Contributes to synaptic loss
- Regulates glutamate receptor trafficking
CSF Biomarker Potential:
- 14-3-3 epsilon detected in cerebrospinal fluid
- Proposed as a biomarker for neuronal damage
- Elevated in AD vs. controls 6
α-Synuclein Regulation:
- 14-3-3 epsilon binds to α-synuclein
- May influence α-synuclein aggregation
- Found in Lewy bodies
- Modulates LB formation 7
LRRK2 Regulation:
- Interacts with leucine-rich repeat kinase 2 (LRRK2)
- May modulate LRRK2 kinase activity
- LRRK2 mutations are a major cause of familial PD
PARK Proteins:
- Interacts with several PARK gene products
- Links to mitochondrial function
- Involved in mitophagy regulation
Neuroprotection:
- Protects dopaminergic neurons
- Regulates mitochondrial integrity
- Modulates oxidative stress responses
Huntington's Disease:
- Altered 14-3-3 expression in HD
- Modulates mutant huntingtin toxicity
- May affect protein aggregation
Amyotrophic Lateral Sclerosis (ALS):
- 14-3-3 epsilon interactions with TDP-43
- Regulates motor neuron survival
- Altered in ALS brain and CSF
Prion Diseases:
- 14-3-3 in CSF as a diagnostic marker
- Modulates prion protein aggregation
- Biomarker for Creutzfeldt-Jakob disease 8
14-3-3 Protein-Protein Interaction Inhibitors:
- Small molecules disrupting 14-3-3 client interactions
- Potential for cancer therapy
- Research stage for neurodegeneration
Stabilizers:
- Compounds enhancing 14-3-3 function
- Potential neuroprotective strategies
- CSF 14-3-3 epsilon as neurodegeneration marker
- Blood-brain barrier integrity indicator
- Disease progression biomarker
¶ Genetics and Variants
- Located on chromosome 17p13.3
- Encodes 255 amino acid protein
- Highly conserved across species
Miller-Dieker Syndrome:
- 17p13.3 microdeletion syndrome
- Includes YWHAE loss
- Lissencephaly, severe developmental defects
Cancer:
- YWHAE rearrangements in certain cancers
- Dysregulated expression in multiple tumors
- Prognostic significance in some cancers
- Western blotting for protein expression
- Immunohistochemistry for brain localization
- ELISA for CSF/blood measurements
- Co-immunoprecipitation for interactions
- Mass spectrometry for proteomics
- Knockout mice (Ywhae -/-)
- Transgenic models with mutant proteins
- Induced pluripotent stem cells (iPSCs)
- Drosophila models
- 14-3-3 proteins: A highly conserved and versatile family. Nature, 1996.
- 14-3-3 proteins in disease. Nat Rev Cancer, 2006.
- Structure of 14-3-3 protein-protein interactions. EMBO J, 2000.
- 14-3-3 expression in brain. J Neurosci, 2001.
- 14-3-3 proteins in Alzheimer's disease brain. J Neuropathol Exp Neurol, 2002.
- Cerebrospinal fluid 14-3-3 in neurodegenerative disease. Neurology, 2005.
- α-Synuclein and 14-3-3 interactions. J Biol Chem, 2002.
- 14-3-3 proteins in prion disease diagnosis. Brain, 2002.